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Porcine reproductive and respiratory syndrome is an important infectious disease of pigs and has a signiﬁcant
harmful effect on the livestock industry, especially in China. PRRSV ORF1b gene encodes primary proteins
which play a vital role during PRRSV replication. In this paper, various 12-amino-acid peptides were
displayed. These peptides could bind to the polymerase and helicase of PRRSV ORF1b protein, respectively, in
which p9 exerted the highest antiviral activity with an IC50 of 56 mM, and the minimum toxicity to cells. It
was proved that p9 inhibited PRRSV replication in infected MARC-145 cells in a dose-dependent manner, and
the amino acid sequence of HRILMRIR was important for antiviral activity of p9. Also, p9 could bind to the cell
membrane and penetrated into cells. These result suggested that p9 might be a potential therapeutic drug for
PRRSV infection.
Crown Copyright & 2012 Published by Elsevier Inc. All rights reserved.Introduction
Porcine reproductive and respiratory syndrome (PRRS) is
caused by porcine reproductive and respiratory syndrome virus
(PRRSV), and is a widespread infectious disease of pigs
(Meulenberg et al., 1993). At the present time, PRRSV is known
to damage the immune system of pigs, and the effect of commer-
cial vaccines to prevent PRRSV infection is limited (Christopher-
Hennings et al., 1995; Mateu and Diaz, 2008). Therefore, it is
urgent to explore new antiviral drugs to control the PRRS.
PRRSV is divided into two major genotypes: the European (EU;
type 1) genotype and the North American (NA; type 2) genotype
(Meng et al., 1995), which is the main type isolated in China. PRRSV is
a single-stranded positive-sense RNA virus of about 15 kB in length.
The genome has a cap structure at its 50-end and a poly(A) tail at its
30-end and encodes nine open reading frames (ORF1a, ORF1b, ORF2a,
ORF2b, ORF3–ORF7). ORF1 and ORF2 encode virus replication-related
proteins, and account for 80% of the virus genome (Mounir et al.,
1995; Nelson et al., 1995). ORF1a and ORF1b encode a polyprotein,
which is proteolytically processed to 12 nonstructural proteins
(NSPs). Among these, ORF1b encoded proteins are RNA-dependent
RNA polymerase (NSP9), helicase (NSP10) and the conserved C-term-
inal domain (CTD) (NSP11) (Fang et al., 2004).These proteins are012 Published by Elsevier Inc. All
n).important factors in the process of virus infection (Castel et al., 2011;
Sergeeva et al., 2006). Therefore, ORF1b can be used as a potential
target for antiviral drug screening.
Phage technology can be used to carry out high-throughput
screening of functional polypeptides, and the polypeptide gene
cloning number in phage peptide libraries can reach more than a
million. This technology has been applied increasingly in drug
development trials, and it is an effective method for the development
of new drugs (Bai et al., 2006; Hall et al. 2009). At present, many
antiviral peptides have been obtained by phage screening technology,
such as inhibition polypeptides of infectious bronchitis virus (IBV)
(Peng et al., 2006), human immunodeﬁciency virus (HIV) (Welch
et al., 2010), hepatitis C virus (HCV) (Hong et al., 2010), hepatitis B
virus (HBV) (Ho et al., 2003), Newcastle disease virus (NDV) and other
viruses (Chia et al., 2006). Some of these polypeptides have reached
the experimental stage. This experiment uses a 12-peptide phage
library to screen 12 peptides for activity against PRRSV ORF1b RNA
polymerase and helicase protein. One peptide was found to interact
with the PRRSV polymerase and suppress virus replication effectively.Results
Identiﬁcation of phage-displayed peptides with PRRSV ORF1B protein
Proteins encoded by PRRSV ORF1b play vital roles during
PRRSV replication. To design inhibitors based on these proteinsrights reserved.
Table 1
List of peptides determined from phage display selection. Peptides P1–P5 are
target to Helicase and P6–P14 are target to Polymerase. C1–C5 are sequences
determined from Escherichia coli control.
Peptide Target Amino acid sequence MW pI GRAVY
P1 Helicase RRRKRPIRRKLR 1691.1 12.78 2.717
P2 Helicase HIRLTLSRNKNT 1452.6 12.01 1.100
P3 Helicase TRTMTMNQNRRS 1495.6 12.30 1.925
P4 Helicase PQTNQTTMKMRM 1466.7 11.01 1.408
P5 Helicase IMPTKKIPPIIM 1381.8 10.00 0.708
P6 Polymerase KKTPPIRIRHRP 1498.8 12.31 1.750
P7 Polymerase NIPIKPRPRLMK 1462.8 12.02 0.867
P8 Polymerase SPHIIRNHRLSK 1457.7 12.01 1.100
P9 Polymerase HRILMRIRQMMT 1586.0 12.30 0.200
P10 Polymerase RIIRKSQRSLMN 1501.8 12.30 0.942
P11 Polymerase RQPRTPMTRLSR 1498.7 12.48 1.767
P12 Polymerase IIRHRSMIITIT 1453.8 12.00 0.833
P13 Polymerase KTRTMQMRNRMP 1549.8 12.30 1.808
P14 Polymerase RMRSKRRKITTR 1588.9 12.60 2.175
C1 Control SPRQIMMHMPKP
C2 Control QRIRRTPQRPMR
C3 Control QMKRMIMMMRRT
C4 Control PRPRKMMMMQSK
C5 Control HIISIIRKQTRP
The molecular weight (MW), pI, and grand average of hydropathicity (GRAVY)
were predicted with the ProtParam algorithm.
Fig. 1. Peptide inhibition of PRRSV infection in MARC-145 cells at 24 h. Primary
screening of antiviral activity of synthetic peptide. Antiviral activity of all peptides
was tested by real-time PCR method. Samples were collected at 24 h after virus
infection. All experiments were repeated at least three times, and all measure-
ments were made in triplicate, mean7standard deviation (SD) is shown (po0.05,
indicated by *) p9 IC50 and CC50. (B) Antiviral activity of p9 by TCID50. (C) Time–
effect and dose–effect of p9 P9 inhibited PRRSV by dose-dependent manner. 12 h,
1000, 500 and 250 mM concentration p9 inhibited virus proliferation markedly.
24 h to 48 h, this dose-dependent inhibition was oberversed more markedly.
Furthermore, the intracellular PRRSV numbers in p9-treated MARC-145 cells were
observed increased in time-dependent manner. (D) Retention period of p9 in
MARC-145 by ﬂuorescence. (E) p9 added at 4 h before and after virus.
K. Liu et al. / Virology 432 (2012) 73–8074controlling virus replication, phage 12-peptide library was used to
screen the peptides binding with ORF1b of PRRSV. After four
cycles of selection, a total of 260 phages were selected and
sequenced, and 20 peptide sequences were ﬁnally obtained by
Clustal W screening and BLAST analysis (Table 1).
Inhibitions of peptides on PRRSV replication in vitro
The inhibition ability of synthetic peptides following phage
displaying was determined by real-time PCR. MARC-145 cells
were inoculated with viruses at 0.01 MOI for 1.5 h at 37 1C, and
treated with or without peptides at 500 mM for 24 h, and cells
treated with DMSO were used as the negative control. The results
showed that p9 peptide exerted the highest antiviral activity
among that of peptides with PRRSV polymerase in vitro (Fig. 1).
The results of Real-time PCR and TCID50 showed that p9 was
the greatest antiviral peptide among all these selected peptides.
Other peptides such as p2, p3 and p13 also showed high antiviral
effects. Furthermore, 500 mM p9 exerted higher antiviral activity
than that of 10 mM ribavirin (Ibarra and Pfeiffer, 2009).
Antiviral activity of p9
To further investigate the antiviral activity of p9, the toxicities
of p9 to MARC-145 cells were detected using MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay.
The results showed that CC50 and IC50 of p9 (24 h) to MARC-
145 cell was 473.00 mM and 56.47 mM, respectively, and CI (CC50/
IC50) of p9 was 8.38 (Fig. 2a). When the concentration of p9 was
250 mM, the ratio of virus copy number/cell reference copy
number was 0.8625, and cell survival rate was 74.54%. The results
of TCID50 are the same as real-time results (Fig. 2b).
To study the time- and dose-dependent effect of p9 on
inhibition of PRRSV replication, MARC-145 cells were incubated
with p9 from 31.25 mM to 1000 mM for the indicated periods at
37 1C. It has been reported that a complete cycle of PRRSV
replication is 24 h (Cafruny et al., 2006). As shown in Fig. 2c,
during PRRSV replication (12 h), 1000 mM, 500 mM and 250 mM p9
showed signiﬁcant inhibition on PRRSV replication. After 24 h, p9
exerted inhibition on intracellular PRRSV numbers of MARC-145
cells in dose-dependent manner. Furthermore, during the secondreplication cycle (36 h and 48 h), with increasing doses of p9, the
intracellular PRRSV numbers of MARC-145 cells treated with p9
were gradually decreased. Furthermore, cytotoxicity in these two
points was very low (data not shown). These results suggested
that p9 inhibits PRRSV replication in a dose-dependent manner.
To detect the intracellular retention time of p9 which is a
potential important antiviral factor, MARC-145 cells were treated
with rhodamine-labeled p9, respectively. Results of light inten-
sity/scanning area of ﬂuorescence gray scanning showed that the
retention time of p9 in cells was at least up to 144 h, and at 24 h,
the ﬂuorescence intensity of rhodamine-p9 is highest among all
indicated times. However, at 48 h and 72 h, the intensities of
rhodamine-p9 were decreased, compared to that of 24 h. Subse-
quently, ﬂuorescence levels were dramatically reduced, and were
almost not observed after 96 h (Fig. 2d).
To further study the inhibition effects of p9, p9 was added for
4 h before and after virus infection and at 0 h after virus infection,
respectively (Fig. 2e). The results of Real-time PCR showed that at
24 h, the intracellular PRRSV numbers in PRRSV-infected MARC-
145 cells pre-incubated with p9 for 4 h or 0 h were dramatically
decreased, compared to that of DMSO control. Although PRRSV
RNA of MARC-145 cells treated with p9 after PRRSV infection
were lower than that of DMSO control, it was signiﬁcantly higher
than that of pre-incubated with p9 for 4 h or 0 h. Also, results at
48 h were similar that of 24 h. These results suggested that p9
stimulation before or together with PRRSV infection could
strongly inhibit PRRSV replication in MARC-145 cells.P9 penetrates cells
As an antiviral peptide, we detected penetration of p9 in
MARC145 cells. Results showed p9 could adsorb to cell mem-
branes in a short time (2 h), and could penetrate into the
cytoplasm within 24 h. These results were observed in other cells
too (data not shown) (Fig. 3).
Fig. 2. P9 inhibition of PRRSV replication: (A) real-time PCR and MTT method were use to detect P9. IC50¼56.47, CC50¼473. (B) Antiviral activity of p9 determined by
TCID50, 500 mM p9 was added and CPE was recorded at 48 h. (C) Determination of the time–effect and dose–effect relationships of p9 on inhibition of virus replication, the
experiment measured the inhibition efﬁciency within 12–48 h. (D) Fluorescence observation of duration of rhodamine-labeled p9 in cells, experiments were determined
within 24–144 h. (E) Determination of the inhibition efﬁciency of p9 added at 4 h before and after virus infection, and carried out 24 h and 48 h (po0.05, indicated by *;
po0.01, indicated by **).
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Peptide inhibition drugs play an antiviral role based on their
amino acid structure (Castel et al., 2011). To study the structure–
activity relationship of p9, the amino acid in p9 was individually
replaced by alanine (A) (Cunningham and Wells, 1989). As shown
in Table 2, analysis results showed that although the molecular
weights and isoelectric points of these mutated peptides were
almost not changed, the solubilities were affected with the
substitution of different positions of amino acids. For example,
the solubilities of these mutated peptides with substitution of the
1st, 2nd, 6th, 8th or 12th amino acid were decreased, while of 3rd,
4th, or 7th amino acid were increased, respectively, and other
replacements were little changed. Compared with the inhibition
activity of these mutant peptides, the results showed that the
antiviral activities of only the mutated peptides with the replace-
ment of 3rd or 9th amino acid were increased, and other
mutations had little effect on the activity and even reduced the
activity. These results suggested that the solubility of peptide was
not directly related to its antiviral activity.
Additionally, the CC50 and IC50 values of these mutants were
measured, which represent the concentration of drug that is
required to kill 50% of the cells in an uninfected culture, and
represents the concentration of a drug that is required for 50%
inhibition of viral replication in vitro, respectively. The results of
CC50 values showed that only the mutated p9 with 12th amino
acid was cytoxic. Also, the IC50 values of 3-p9 and 9-p9 were
lowest among all these mutated p9, which was 34.18 and 34.14,
respectively, indicating that both amino acid positions were
directly involved in the antiviral activity of p9 (Table 2).Fig. 3. P9 adsorbs to and penetrates to cells. Rhodamine-labeled p9 was incubated
with cells for 60 min. Cells were washed and then incubated for an additional
120 min (top panels) or 24 h (bottom panels) before ﬁxation for ﬂuorescence
microscopy: (A) comparison of D-p9 and L-p9 by IC50, (B) comparison of D-p9 and
L-p9 and (C) CD spectrogram of p9.
Table 2
Modiﬁed of p9 sequence (IC50 and CC50 were shown in table).
Modiﬁed peptide Amino acid sequence MW
1-P9 ARILMRIRQMMT 1519.9
2-P9 HAILMRIRQMMT 1500.9
3-P9 HRALMRIRQMMT 1543.9
4-P9 HRIAMRIRQMMT 1453.9
5-P9 HRILARIRQMMT 1525.9
6-P9 HRILMAIRQMMT 1500.9
7-P9 HRILMRARQMMT 1543.9
8-P9 HRILMRIAQMMT 1500.9
9-P9 HRILMRIRAMMT 1528.9
10-P9 HRILMRIRQAMT 1525.9
11-P9 HRILMRIRQMAT 1525.9
12-P9 HRILMRIRQMMA 1555.9
a-p9 LMRIRQMMT 1179.55
b-p9 HRILMRIR 1094.41
c-p9 LMRIR 687.92
D-P9 HRILMRIRQMMT 1585.06
The molecular weight (MW), pI, and grand average of hydropathicity (GRAVY) werTo further study the relationship of the 3rd and 9th amino acid
with p9 antiviral activity, p9 was truncated into three fragments,
including a-p9, b-p9 and c-p9. The results showed that the IC50
value of b-p9 was lowest among these three truncated p9,
suggesting the strongest the antiviral activity. Also, the solubility
of b-p9 was hydrophilicity, whereas a-p9 and c-p9 were hydro-
phobic. These results suggested that b-P9 with sequence of
HRILMRIR might be important for antiviral activity.
It has been reported that the enzymolysis and biological
activity of dextral and levorotatory proteins are different. To
study the discrimination of p9 chirality on antiviral activity,
MARC-145 cells were treated with or without the dextral p9 (D-
p9) and levorotatory p9 (L-p9) (Fig. 4). The results showed that
the IC50 value of D-p9 was 16.12, which was lower than that of
L-p9 (56.47), suggesting that the antiviral activity of D-p9 might
be higher than that of L-p9 (Fig. 4a).
To compare antiviral activities of D-p9 with L-p9, the concen-
trations of 250 mM and 125 mM were used to detect the intracel-
lular PRRSV numbers of MARC-145 cells. The results showed that
the intracellular PRRSV numbers of MARC-145 cells with D-p9
treatment were signiﬁcant lower than that of L-p9 treatment at
24 h, suggesting that the antiviral activity of D-p9 might be higher
than that of L-p9 (Fig. 4b).
Circular dichroism spectroscopy was used to scan p9 at 210–
500 nm wavelengths. A negative peak (97.1972) at 245 nm and
some miscellaneous peaks at 240–210 nm were obtained (Kumar
et al., 2008). In circular dichroism spectroscopy assay, a negative
peak at 245 nm represents a four-chain structure material in the
assay sample. Circular dichroism spectroscopy assay of p9
showed the peptide has a positive peak at 265 nm and a negative
peak at 245 nm. P9 did not fully comply with the proﬁle of a
standard four-chain structure that, and its structure was complex
(Fig. 4c).P9 interacts with the PRRSV polymerase in cells directly
To determine whether P9 interacts with the PRRSV polymerase
intracellularly, we employed a newly developed technique,
known as bimolecular ﬂuorescence complementation (BiFC). BiFC
is based on the principle that two interacting proteins individu-
ally fused to the N- and C-terminal fragments of a ﬂuorescent
protein can bring the two halves of the ﬂuorescent protein into
close, thereby facilitating reconstitution of the ﬂuorophore. BiFC
assays allow for the visualization and localization of speciﬁc
protein–protein interactions within living cells.pI GRAVY IC50 (mM) CC50 (mM)
12.30 0.217 56.12263 4500
12.00 0.325 Undetected Undetected
12.30 0.425 34.18095 4500
12.30 0.367 54.5872 4500
12.30 0.208 435.4996 4500
12.00 0.325 Undetected 4500
12.30 0.425 150.1405 4500
12.00 0.325 60.60846 Undetected
12.30 0.242 34.13563 4500
12.30 0.208 57.98146 4500
12.30 0.208 120.5239 4500
12.00 0.008 89.41235 186.2536
12.00 0.089 263.8101 4500
12.30 0.250 43.50202 4500
12.00 0.240 716.4193 4500
2 mg/ml 16.12312 Undetected
e predicted with the ProtParam algorithm.
Fig. 4. Comparison of time–effect and dose–effect between levorotatory p9 (L-p9)
and dextral p9 (D-p9): (A) L-p9 and D-p9 IC50 comparison, D-Pp IC50¼16.12, L-p9
IC50¼56.47. (B)Two concentrations of 250 and 125 M and two time points of 24 h
and 48 h were selected. (C) CD spectrogram of p9 dissolved in DMSO; a stronger
negative peak was visible at 245 nm (po0.05, indicated by *).
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protein, for the BiFC assays in our study. We ﬁrst split the
ﬂuorescent protein between amino acid residues 173 and 174 to
generate two fragments, VN and VC. As expected, neither VN nor
VC alone produced a ﬂuorescent signal when expressed in MARC-
145 cells (data not shown). Likewise, co-expression of VN and VC
also produced no ﬂuorescence (Fig. 5b). We then generated full-
length polymerase and helicase genes to fuse into the N-terminus
of VN with a ﬂexible linker and designated them VN-polymerase
and VN-helicase, respectively. We generated p9 and mutant p9gene to fuse into N-terminus of VC with a ﬂexible linker and
designated them VC-p9 and VC-mp9, respectively. In order to
determine whether BiFC can efﬁciently detect the p9-polymerase
interactions in living cells, cells were co-transfected with different
combinations and examined for ﬂuorescence. At 14 h post-trans-
fection, we found that ﬂuorescence, representing the p9-poly-
merase interaction, was observed in cytoplasm (Fig. 5b). The VN-
helicase/VC-p9 and VN-polymerase/VC-mp9 pairs were employed
as negative controls, when transfected into living cells neither
produced positive BiFC signals (Fig. 5b).Discussion
In recent years, PRRSV infection has seriously harmed the pig
industry. PRRSV infection has caused great economic loss, espe-
cially in the years 2005–2008. To date, there is no effective drug
that can control PRRSV infection, and PRRSV vaccination is
ineffective. In this study, we expressed the key proteins involved
in PRRSV replication and used phages display to screen for high-
afﬁnity peptides. A number of peptides, in particular p9, showed
very high antiviral activity.
PRRSV polymerase is an RNA-dependent RNA polymerase and
is an enzyme speciﬁc to viruses. Therefore, peptides screened by
phages could play a role in inhibiting this speciﬁc virus enzyme in
cells, and without affecting cell enzyme activity. RNA-dependent
RNA polymerase is one of the most important proteins for
intracellular replication of viruses, and its concentration can be
determined directly by the copy number of the virus gene (Cheng
et al., 2008). Therefore, this approach was used initially to
evaluate the inhibition ability of peptides directly by detection
of the intracellular virus copy number. Nearly all our selected
peptides showed antiviral ability. Among these peptides, the
inhibition ability of p9 was the strongest of the peptides tested.
Therefore, p9 was selected as the peptide molecule for study. This
study used real-time PCR to assess the inhibition ability of p9,
namely to assess the inhibition ability of p9 on polymerase.
Peptide inhibitors can be degraded and metabolized by intra-
cellular proteases after they enter the cell (Mu¨nch et al., 2007).
Stability in cells was an important index to evaluate antiviral
peptide. After viruses have invaded cells, they persist and form
new virus particles, which results in transmission of infection
from one cell to another. This process requires that virus inhibi-
tors exist stably in cells for a prolonged time (Hinson and
Cresswell, 2009; Wolf et al., 2010). Once virus replication has
occurred, p9 inhibitory effect on viruses can act. Our study
detected and observed the time of p9 peptide inhibition of viruses
and the duration of p9 peptide in cells. Our results indicated that
p9 at high concentrations could play an inhibitory role in cells for
a prolonged period. Virus concentration in cells increased with
time, but when compared with the PBS control group, the
quantity of virus and speed of virus increase were both lower in
the presence of p9. In an antiviral time–effect trial, detection of
intracellular virus copy number at 72 h showed that inhibition
effect of p9 could last up to 72 h (data not shown). Because of our
chosen calculation method, we saw variation in virus copy
number only in the ﬁrst 48 h. The intracellular degradation and
metabolic rate of p9 showed discontinuous variation. At 48 h,
intracellular p9 concentration was high, and the corresponding
virus replication was also inhibited strongly. After 48 h, ﬂuores-
cence observation showed that p9 concentration was still high. At
96 h, p9 concentration was low as seen by ﬂuorescence observa-
tion. We speculated the p9 was degraded or metabolized quickly
(ﬂuorescence gray scanning results) in the 48–96 h period. For the
virus infected group in the corresponding 48–96 h, many cells
died. Fluorescence observation of intracellular duration of p9
Fig. 5. BiFC assay of p9 and polymerase interactions intracellular: (A) the design of ﬂuorescence plasmids and (B) the ﬂuorescence visualized in living cells. M-p9 was
designed with p9 amino acid elements and used as a negative control.
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decreased slowly.
We further tested the inhibitory effect of p9 added at 4 h
before and after virus inoculation, which represented the virus
prevention and the treatment effects of p9. The results showed
that p9 added before cell infection had higher antiviral ability
than p9 added at 0 h or 4 h after cell infection. In the þ4 h group,
p9 was added at 4 h after viruses had infected cells, and we
calculated that p9 entered the cells probably at 5–6 h. In this 5–
6 h period, viruses had enough time to complete intracellular
capsid removal and polymerase expression (You et al., 2008;
Cheng et al., 2008; Konduru and Kaplan, 2010). Based on these
results, we suggest that p9 plays an inhibitory role, and that its
inhibition efﬁciency was comparatively much lower than that of
the 4 h group and of that of the 0 h group. However, the
inhibitory effect of p9 could still be detected.
The amino acid composition of p9 makes it weakly hydrophilic
(GRAVY¼0.200). Compared with other screened peptides, it was
in the mid range, i.e. the remaining peptides were more hydro-
phobic (0.833) or hydrophilic (2.717), but their antiviral activity
was less than that of p9. Adjacent amino acid mutations in p9
showed that the GRAVY properties of the mutant peptides had no
correlation with antiviral activity. Both mutation to hydrophobic or
hydrophilic residues resulted in either high or low activity. It was
found that mutations at the third and ninth amino acid sites
increased the antiviral activity of the peptide. We speculated that
the two mutations to alanine sites could expose the active area of
the peptide, which aided peptide and polymerase combination. To
further study the active center positions of p9, we truncated p9 by
removal of either the N-terminus end, C-terminus end or of both
ends. The results showed that removal of four amino acids at the
C-terminus end increased the activity of the peptide, while theactivities of the other truncated peptides decreased in comparison.
This ﬁnding indicated that the active area of p9 was mainly in the
eight amino acids at the N-terminus end. Therefore, we speculated
that the active center of p9 and the key amino acids that determined
the activity were discontinuous (Bajorath et al., 2009; Wawer and
Bajorath, 2009). This situation is similar to that found for B-cell
epitopes, which are composed of discontinuous amino acids. Circu-
lar dichroism spectroscopy results showed that p9 had an obvious
negative peak at 245 nm, but had no peak 265 nm, a ﬁnding which
is possibly typical of peptides with more complex structures (Olga
et al., 2009). However, there were many hybridized peaks at 240–
220 nm, which were possibly caused by interference by the p9
solvent DMSO. We speculated that p9 does not form a ﬁxed
structure in DMSO, and that its status varied with environmental
changes (Shen et al., 2000).
We compared dextral p9 (D-p9) and levorotatory p9 (L-p9)
and found that the inhibition activity of dextral p9 was much
higher than that of levorotatory p9, a ﬁnding that is in line with
other research results (Zeng and Sabra, 2011). Dextral p9 proteins
are degraded more slowly in vivo, which allows D-p9 to have a
more effective inhibitory role.
Our BiFC experiments showed interaction between p9 and the
PRRSV polymerase. These results demonstrate that p9 interacts
with the polymerase itself rather than with PRRSV nucleic acid
associated with the polymerase.
Our studies show that the PRRSV Polymerase is an attractive
drug target. Furthermore, we found that p9 and p9 derivatives are
potent antiviral peptide with low cytotoxic even at exceedingly
high concentrations. Importantly, a few amino acid changes result
in increasing the antiviral potency of p9. Thus, further develop-
ment of p9 as an antiviral agent may lead to a new polymerase
inhibitors expected to inhibit PRRSV.
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Cells and plasmid
MARC-145 cells, Vero cells, BHK-21 cells, and RK-13 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM), supple-
mented with 10% fetal bovine serum (FBS, Gibco). The two protein
genes of polymerase and helicase in ORF1b of PRRSV (SY0608)
were cloned into the pCOLD plasmid or the pET-32a(þ) plasmid
(Hayashi and Kojima, 2008), respectively.
Expression and puriﬁcation
The plasmids containing three protein genes (polymerase or
helicase) were transfected into Rosetta or R2 host bacteria,
respectively, and these proteins were expressed after induction,
and were puriﬁed with Ni afﬁnity according to the manufacturer’s
instructions.
Phage display library screening
Selection procedure was slightly modiﬁed following with the
manufacturer’s protocol. Brieﬂy, the Ph.D.-12TM Phage Display
Peptide Library (New England Biolabs) was ﬁrst exposed to plates
coated with three puriﬁed recombinant PRRSV proteins, respec-
tively. Unbound phages were washed away, and the bound
phages were eluted and ampliﬁed for the second screening round.
These phages that showed high binding activity to recombinant
proteins by an indirect enzyme-linked immunosorbent assay
were selected and sequenced from the fourth round selection,
and then analyzed to determine the homology proteins using
BLAST software (http://ncbi.nlm.nih.gov/BLAST/). All peptides
were chemically synthesized by TASH Biotechnology Co. Ltd with
purity of more than 95%, and were dissolved in DMSO.
Real-time polymerase chain reaction (PCR) and tissue culture
infective dose (TCID50) assay
The effects on PRRSV of peptides treatment were determined
with both real-time PCR and TCID50 methods. Simply, total RNA
was prepared using TRizol reagent (Invitrogen) from cells treated
with or without peptides or drugs. Reverse Transcription was
performed following manufacturer protocols (Invitrogen). Brieﬂy,
2 ml total RNA, 1 ml 10 mM dNTP Mix, 2 pmole gene-speciﬁc
reverse primer and 8.8 ml distilled water were added to a
nuclease-free microcentrifuge tube. Mixtures were heated to
65 1C for 5 min and quick chill on ice for 5 min. Then 4 ml 5
First-Strand Buffer, 2 ml 0.1 M DTT, 1 ml Ribonuclease Inhibitor
and 1 ml M-MLV was added. Tubes were incubated at 42 1C for
50 min and 75 1C for 15 min. To remove RNA complementary toTable 3
Primers and probes used in this study.
Name Primers
PRRSV F: 5’–AGTGGGTCGGCACCAGTT-3’ R: 5’–GCAGACAAATCCAGAGG
MARC-145 beta
actin
F: 5’–CAGCACGATGAAGATCAA-3’ R: 5’–GGGTGTAACGCAACTAA
VN-polymerase F: 5’–TATAGATCTATGCTAGCCGCCAGCGGCTTGACCCGC-3’
R: 5’–GCGCTCGAGCCCCTCATGATTGGACCTGAGTTTTTC-3’
VN-helicase F: 5’–GTGGAATTCGGGAAGAAGTCCAGAATGTGCGGG-3’ R: 5’–T
VC-p9 F: 5’–TATAGATCTATGCACAGGATACTCATGCGGATTCGACAGA-3’
R: 5’–CGACTCGAGAGTCATCATCTGTCGAATCCGCATGAGTA-3’
VC-Mp9 F: 5’–ATAAGATCTATGGATGATCCGCCACCGCATGACC-3’ R: 5’–
ACGCTCGAGGCGCATGATGGTCATGCGGTGGCG-3’the cDNA, 1 ml E. coli RNase H was added and incubated at 37 1C
for 20 min. Real-time PCR was performed using Taqman probe
quantitative real-time PCR following manufacturer protocols
(TaKaRa). The primers and probes used for PCR are shown in
Table 3. Results are expressed as virus RNA copies, which were
normalized to b-actin copy numbers as the endogenous control.
Also, TCID50 was determined by Reed–Muench method according
to the previous report (Sachs et al., 2011).Cytotoxicity assay
MARC-145 cells were incubated with or without peptides
(from 1 to 500 mM or 1000 mM) for 24, 36, and 48 h. CC50 was
determined using MTT assay. Brieﬂy, MARC-145 cells were
incubated in 96-well plates in 200 ml of DMEM. Incubation was
terminated by aspirating the media and MTT solution (5 mg/ml in
PBS) were added to each well. Formazane formation was termi-
nated after 4 h by removing the MTT solution. Subsequently
DMSO was added to each well to solubilize formazane, and the
formazane-containing samples were measured at 590 nm in a
microplate reader.Fluorescence microscopy
MARC-145 cells were treated with or without peptide at
various time points. After ﬁxation in 80% ice-cold acetone at
20 1C for 10 min, cells were stained with 3,3-dioctadecyloxa-
carbocyanine perchlorate (DiO) for 3 min and stained with 4’,6-
diamidino-2-phenylindole (DAPI) for 10 min. After washing, cells
were detected and photographed with ﬂuorescence microscopy.Bimolecular ﬂuorescence complementation (BiFC) assay
A variant of yellow ﬂuorescent protein, Venus, was obtained
by site-directed mutagenesis of pEYFP-N1 (BD-Clontech). As
shown in Fig. 5a, sequences encoding the amino- (residues 1 to
173, VN) or carboxyl- (residues 174 to 239, VC) fragments of
Venus were fused to the C-terminus of the full-length or trun-
cated N proteins via a (GGGGS)x3 linker (Shimozono and
Miyawaki, 2008; Shyu et al., 2006). We also ampliﬁed the Heli-
case gene from PRRSV to be fused to the N-termini of VN and
mutant p9 (mp9) (LQMIRHRMTIMR) to the VC for use as negative
controls. The primers used for BiFC are shown in Table 3. MARC-
145 cells cultured in 6-well plates to about 60% conﬂuency were
co-transfected with 500 ng of each BiFC plasmid using the Lip
2000 Transfection Reagent. At 14 h post-transfection, live cells
were visualized using an Olympus inverted ﬂuorescence
microscope.Probe or sequences
CTCAT-3’ FAM’–CGTAGAACTGTGACAAC-
BHQ1
G-3’ FAM’–CGTAGAACTGTGACAAC-
BHQ1
Polymerase
ATCTCGAGTTTATGGATAGGGCGAAGGCT-3’ Helicase
HRILMRIRQMMT
LQMIRHRMTIMR
K. Liu et al. / Virology 432 (2012) 73–8080Statistical analyses
All assays described here were repeated at least twice, and all
the measurements were made in triplicate. Mean values7stan-
dard deviation (SD) were calculated using Microsoft Excel. Statis-
tical analysis was done by one-way analysis of variance and
values were considered signiﬁcant or when po0.05. Figures were
performed using the GraphPadTM Prism 5.0 software.Acknowledgments
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